Natural killer cell therapy - Shenzhen Hank Bioengineering Institute

Drug Profile

Natural killer cell therapy - Shenzhen Hank Bioengineering Institute

Alternative Names: HANK cell - Shenzhen Hank Bioengineering Institute; High-activity natural killer cells - Shenzhen Hank Bioengineering Institute; Natural killer immunotherapy - Shenzhen Hank Bioengineering Institute

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HANK Bioengineering
  • Developer Fuda Cancer Hospital; HANK Bioengineering
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II B cell lymphoma; Breast cancer; Cervical cancer; Colorectal cancer; Laryngeal cancer; Liver cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Pharyngeal neoplasms; Renal cancer; Soft tissue sarcoma; Tongue cancer

Most Recent Events

  • 17 Nov 2017 Shenzhen Hank Bioengineering Institute plans a clinical trial for HIV infections in China in January 2018 (ChiCTR-INR-17013337)
  • 01 Dec 2016 Phase-I/II clinical trials in Colorectal cancer (Second-line therapy or greater, Metastatic disease, Recurrent) in China (IV) (NCT03008499)
  • 01 Dec 2016 Phase-I/II clinical trials in Liver cancer (Second-line therapy or greater, Recurrent) in China (IV) (NCT03008343)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top